Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM5 | Q9NZQ8 | 14/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1224766 | 1.00 | TRPM5 (1.00) | TRPM5LMNASMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL2779326 | 1.00 | TRPM5 (1.00) | TRPM5LMNASMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL1224770 | 1.00 | TRPM5 (1.00) | TRPM5LMNASMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL1224765 | 1.00 | TRPM5 (1.00) | TRPM5LMNASMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL1224762 | 0.92 | TRPM5 (1.00) | TRPM5LMNASMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL1224851 | 0.92 | TRPM5 (1.00) | TRPM5LMNASMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL1224761 | 0.92 | TRPM5 (1.00) | TRPM5LMNASMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL2782451 | 0.92 | TRPM5 (1.00) | TRPM5LMNASMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL1224849 | 0.92 | TRPM5 (1.00) | TRPM5LMNASMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL1224064 | 0.91 | TRPM5 (1.00) | TRPM5LMNASMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110033393-A1 | Hydrazone Compounds and Their Use | REDPOINT BIO CORPORATION | 2011-02-10 | — | — | US | claimed |
| US-20110033393-A1 | Hydrazone Compounds and Their Use | REDPOINT BIO CORPORATION | 2011-02-10 | — | — | US | disclosed |
| US-20110033393-A1 | Hydrazone Compounds and Their Use | REDPOINT BIO CORPORATION | 2011-02-10 | — | — | US | disclosed |
| US-20110033393-A1 | Hydrazone Compounds and Their Use | REDPOINT BIO CORPORATION | 2011-02-10 | — | — | US | disclosed |
| WO-2010132615-A1 | HYDRAZONE COMPOUNDS AND THEIR USE | STEIN PHILIP (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110033393-A1 | Hydrazone Compounds and Their Use | TRPM5, TRPV5, TRPM8 | TRPM5 1/4885LMNA 2883/4885SMN1; SMN2 3444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.